

FAX RECEIVED

1632

08/06/03 12:42 8602860115

CANTOR COLBURN L

AUG 07 2003

001/007

GROUP 1600

## CERTIFICATE OF TRANSMISSION BY FACSIMILE (37 CFR 1.8)

Applicant(s): HLA, et al.

Docket No.

UCT-0012-P

Serial No.  
09/945,353Filing Date  
August 31, 2001Examiner  
M. SchmidtGroup Art Unit  
1635

Invention: METHOD FOR REGULATING ANGIOGENESIS

I hereby certify that this Response to Restriction Requirement (4 pgs); Certificate of Transmission (1 pg)  
(Identify type of correspondence)is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. (703) 872-9307)on August 6, 2003  
(Date)

Marjorie R. Humes

(Typed or Printed Name of Person Signing Certificate)

Marjorie R. Humes  
(Signature)

Note: Each paper must have its own certificate of mailing.

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Small Entity)**Docket No.  
UCT-0012-P

In Re Application Of: HLA, et al.

Serial No.  
09/945,353Filing Date  
08/31/2001Examiner  
Mary M. SchmidtGroup Art Unit  
1635Invention: **METHOD FOR REGULATING ANGIOGENESIS**TO THE COMMISSIONER FOR PATENTS:

This is a combined amendment and petition under the provisions of 37 CFR 1.136(a) to extend the period for filing a response to the Office Action of 06-11-2003 in the above-identified application.  
Date

The requested extension is as follows (check time period desired):

☒ One month    ☐ Two months    ☐ Three months    ☐ Four months    ☐ Five months

from: 07-11-2003 until: 08-11-2003  
Date Date

A verified statement of small entity status as a small entity under 37 CFR 1.27:

- ☐ is enclosed.  
☐ has already been filed in this application.

The fee for the amendment and extension of time has been calculated as shown below:

**CLAIMS AS AMENDED**

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	12 -	20 =	0	x \$9.00	\$0.00
INDEP. CLAIMS	0 -	3 =	0	x \$42.00	\$0.00
FEE FOR AMENDMENT					\$0.00
FEE FOR EXTENSION OF TIME					\$55.00
TOTAL FEE FOR AMENDMENT AND EXTENSION OF TIME					\$55.00

**COMBINED AMENDMENT & PETITION FOR EXTENSION OF  
TIME UNDER 37 CFR 1.136(a) (Small Entity)**Docket No.  
UCT-0012-P

The fee for the amendment and extension of time is to be paid as follows:

- ☐ A check in the amount of \$55.00 for the amendment and extension of time is enclosed.
- ☒ Please charge Deposit Account No. 06-1130 in the amount of \$55.00
- ☒ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 06-1130
- ☒ Any additional filing fees required under 37 C.F.R. 1.16.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ If an additional extension of time is required, please consider this a petition therefor and charge any additional fees which may be required to Deposit Account No. 06-1130

  
Signature

Dated: August 6, 2003

Karen A. LeCuyer  
Registration No. 51,928  
Customer No. 23413I certify that this document and fee is being deposited  
on with the U.S. Postal Service  
as first class mail under 37 C.F.R. 1.8 and is addressed to  
the Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450.

Signature of Person Mailing Correspondence

VIA FACSIMILE TRANSMISSION

Typed or Printed Name of Person Mailing Correspondence

CC:

F28SMALL/REV03

UCT-0012P

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	TIMOTHY HLA ET AL	)	
		)	Group Art: 1635
Serial No.:	09/945,353	)	
		)	Examiner: Schmidt, M.
Filed:	August 31, 2001	)	
		)	
For:	METHOD FOR REGULATING	)	
	ANGIOGENESIS	)	

## RESPONSE TO RESTRICTION REQUIREMENT

VIA FACSIMILE TO: (703) 872-9307

Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

Sir:

This is responsive to the restriction requirement dated June 11, 2003. A Request for Extension of Time for one month from July 11, 2003 to August 11, 2003 is submitted herewith.

## CLAIMS:

1. (original) A method to inhibit angiogenesis in vivo, comprising administration of a composition comprising a pharmaceutically effective quantity of an antagonist of EDG-1 signal transduction.
2. (original) The method of claim 1, wherein the composition further comprises at least one additional anti-angiogenic factor.
3. (original) The method of claim 1, wherein the composition further comprises a PI-3-kinase inhibitor.
4. (original) The method of claim 1, wherein the composition further comprises an Akt kinase inhibitor.
5. (original) The method of claim 1, wherein the composition further comprises wortmannin.
6. (original) The method of claim 1, wherein the composition further comprises LY294002.
7. (original) The method of claim 1, wherein the composition further comprises the DNA sequence encoding a mutated EDG-1 receptor.
8. (original) The method of claim 7, wherein the mutated EDG-1 receptor is T236A, R231K or R233K.
9. (original) A method for treatment of unwanted angiogenesis in a human or animal, comprising administration of a composition comprising a pharmaceutically effective quantity of an antagonist of EDG-1 signal transduction.
10. (original) The method of claim 9, wherein the composition further comprises an anti-EDG-1 antibody.

11. (original) The method of claim 10, wherein the anti-EDG-1 antibody is a chicken-anti-human-EDG-1 antibody.

12. (original) The method of claim 10, wherein the anti-EDG-1 antibody is a biologically active fragment.

REMARKS

Applicants hereby elect to prosecute Group III, Claims 1, 4 and 9 drawn to a methods of administration of an antagonist of EDG-1 signal transduction, further comprising an AKT kinase inhibitor, with traverse.

If there are any additional charges with respect to this Response or otherwise, please charge them to Deposit Account No. 06-1130 maintained by Cantor Colburn LLP.

Respectfully submitted,

TIMOTHY HLA ET AL

CANTOR COLBURN LLP  
Applicants' Attorneys

By: Karen A. LeCuyer  
Karen A. LeCuyer

Date: June 8, 2001  
Customer No.: 23413  
Telephone: (860) 286-2929